Juniper and Crystec sign agreement for next generation medicines

Written By Becky Murphy

Crystec and Juniper Pharma Services are working together as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI) project ReMediES (Re-configuring medicines end-to-end supply)

Crystec and Juniper Pharma Services are working together as part of the Advanced Manufacturing Supply Chain Initiative (AMSCI) project, ReMediES. Juniper Pharma Services will bring its expertise in characterisation, formulation development and GMP production to the supercritical fluid (SCF) manufacturing platform, ultimately reshoring this high value manufacturing process to the United Kingdom. 

Read the full press release here: http://www.juniperpharma.com/juniper-and-crystec-sign-agreement-for-next-generation-medicines/ 

For more information, contact info@crystecpharma.com 

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.

Becky Murphy
Previous

REMEDIES moves on to next stage
Next

Crystec case study in Nesta report